Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 10/20 | 0.69 |
| ▸ | CDK1 | P06493 | 2/20 | 0.69 |
| ▸ | CDK2 | P24941 | 2/20 | 0.69 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.69 |
| ▸ | GSK3B | P49841 | 1/20 | 0.69 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.69 |
| ▸ | PARP1 | P09874 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13866222 | 1.00 | CDK4 (0.69) | CDK4CDK1CDK2CDK6GSK3B | |
| SCHEMBL13866230 | 0.94 | CDK4 (0.68) | CDK4CDK1CDK2CDK6GSK3B | |
| SCHEMBL13866235 | 0.91 | CDK4 (0.65) | CDK4CDK1CDK2CDK6GSK3B | |
| SCHEMBL13865806 | 0.88 | CDK4 (0.70) | CDK4CDK1CDK2CDK6GSK3B | |
| SCHEMBL13865811 | 0.87 | CDK4 (0.68) | CDK4CDK1CDK2CDK6GSK3B | |
| SCHEMBL13866278 | 0.87 | CDK4 (0.68) | CDK4CDK1CDK2CDK6GSK3B | |
| SCHEMBL13865807 | 0.87 | CDK4 (0.69) | CDK4CDK1CDK2CDK6GSK3B | |
| SCHEMBL13866287 | 0.87 | CDK4 (0.69) | CDK4CDK1CDK2CDK6GSK3B | |
| SCHEMBL13865805 | 0.87 | CDK4 (0.69) | CDK4CDK1CDK2CDK6GSK3B | |
| SCHEMBL13866288 | 0.87 | CDK4 (0.69) | CDK4CDK1CDK2CDK6GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137597-A1 | Novel quinoxalinone derivatives | MSD K.K. (JP) | 2009-05-28 | — | — | US | disclosed |
| US-20090137597-A1 | Novel quinoxalinone derivatives | MSD K.K. (JP) | 2009-05-28 | — | — | US | disclosed |
| US-7388010-B2 | Quinoxalinone derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-06-17 | — | — | US | disclosed |
| US-7388010-B2 | Quinoxalinone derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137597-A1 | Novel quinoxalinone derivatives | NDUFB1, NDUFB6, NDUFB7 | CDK4 2691/4885CDK1 1569/4885CDK2 1879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.